The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in ...

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

Every dollar we spend on tariffs is a dollar we can’t spend on research and development,” Sebastian Guth warns, as ...

Biogenesis today launched from stealth, backed by Jack Altman’s Alt Capital. Biogenesis builds an automated feasibility ...

Research and development (R&D) spending by drug manufacturers flatlined in 2022, according to data released by Evaluate Vantage Friday morning. Among the world’s largest 11 drugmakers, only ...

China's pharmaceutical sector, once driven largely by generic drug production, is now witnessing a steady rise in innovative ...

The biotech and pharma Industries are growing healthcare solutions for the future. These locations support the industry's ...

Medicus Pharma has carved out a niche in dermatological therapeutics, focusing on novel compounds and delivery systems ...

The transaction marks a significant consolidation move within India’s pharmaceutical sector, signaling growing momentum for ...

NEW YORK (Reuters) -The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according ...

Pharmaceutical companies are often lambasted for rising drug costs. For example, the price of new drugs entering the US market in 2023 was 35% higher than in 2022. According to an analysis from ...

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.